FeesSafety
Pluang+

RASONQUE plus chemotherapy shows strong results in first-line metastatic pancreatic cancer treatment.

Company Fundamentals
20 Nov 2026, 01:05 WIB
GlobeNewsWire
View Source
Bullish
RASONQUE plus chemotherapy shows strong results in first-line metastatic pancreatic cancer treatment.

Revolution Medicines announced updated Phase 1/2 data showing that RASONQUE (daraxonrasib) combined with gemcitabine and nab-paclitaxel achieved a 60.7% objective response rate and median progression-free survival of 12.8 months in first-line metastatic pancreatic cancer patients. The treatment also demonstrated durable disease control and a 76.6% one-year overall survival rate, supporting ongoing Phase 3 trials. These results highlight RASONQUE's potential as a more effective first-line therapy option for this aggressive cancer with limited current treatments.

Revolution Medicines Inc. (RVMD) trades at USD 159.24 on Pluang as of Nov 20, 2026 06:21 WIB, down 0.36% in one day. The stock's market cap stands at $34.57 billion, with a 52-week high of $221.15 and low of $69.88. Investors hold RVMD shares for an average of 13 days on the platform.

More News (RVMD)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App